Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response
Abstract Advent of tyrosine kinase inhibitors (TKI) have revolutionized therapy of chronic myeloid leukemia. Imatinib was the first agent utilized in the therapy of CML. Nilotinib, a second generation TKI, results in an increase in number of patients achieving major molecular response at an earlier...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-07-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.21 |
| _version_ | 1797740000294469632 |
|---|---|
| author | Shifang Wang Sai Prasad Desikan Jay Jeffrey Charles McClain III Raman Desikan |
| author_facet | Shifang Wang Sai Prasad Desikan Jay Jeffrey Charles McClain III Raman Desikan |
| author_sort | Shifang Wang |
| collection | DOAJ |
| description | Abstract Advent of tyrosine kinase inhibitors (TKI) have revolutionized therapy of chronic myeloid leukemia. Imatinib was the first agent utilized in the therapy of CML. Nilotinib, a second generation TKI, results in an increase in number of patients achieving major molecular response at an earlier time point. Asymptomatic elevations in pancreatic enzyme is common and acute pancreatitis within weeks to months from start of therapy has been observed. Delayed onset pancreatitis has not been reported. We report a case of delayed onset pancreatitis in a patient with sustained complete molecular response. On account of the deep response, we were able to avoid starting alternate tyrosine kinase inhibitors that could also result in pancreatitis as a class effect. |
| first_indexed | 2024-03-12T14:06:14Z |
| format | Article |
| id | doaj.art-ee76ff370f59429384976e993fa36fc3 |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-12T14:06:14Z |
| publishDate | 2020-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-ee76ff370f59429384976e993fa36fc32023-08-21T14:10:49ZengWileyeJHaem2688-61462020-07-011130931110.1002/jha2.21Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular responseShifang Wang0Sai Prasad Desikan1Jay Jeffrey2Charles McClain III3Raman Desikan4White River Health System Batesville Arizona USAWhite River Health System Batesville Arizona USAWhite River Health System Batesville Arizona USAWhite River Health System Batesville Arizona USAWhite River Health System Batesville Arizona USAAbstract Advent of tyrosine kinase inhibitors (TKI) have revolutionized therapy of chronic myeloid leukemia. Imatinib was the first agent utilized in the therapy of CML. Nilotinib, a second generation TKI, results in an increase in number of patients achieving major molecular response at an earlier time point. Asymptomatic elevations in pancreatic enzyme is common and acute pancreatitis within weeks to months from start of therapy has been observed. Delayed onset pancreatitis has not been reported. We report a case of delayed onset pancreatitis in a patient with sustained complete molecular response. On account of the deep response, we were able to avoid starting alternate tyrosine kinase inhibitors that could also result in pancreatitis as a class effect.https://doi.org/10.1002/jha2.21CML leukemiaCML MDRtherapy |
| spellingShingle | Shifang Wang Sai Prasad Desikan Jay Jeffrey Charles McClain III Raman Desikan Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response eJHaem CML leukemia CML MDR therapy |
| title | Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response |
| title_full | Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response |
| title_fullStr | Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response |
| title_full_unstemmed | Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response |
| title_short | Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response |
| title_sort | delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response |
| topic | CML leukemia CML MDR therapy |
| url | https://doi.org/10.1002/jha2.21 |
| work_keys_str_mv | AT shifangwang delayedacutepancreatitisinducedbynilotinibinapatientwithchronicmyeloidleukemiaattainingsustainedcompletemolecularresponse AT saiprasaddesikan delayedacutepancreatitisinducedbynilotinibinapatientwithchronicmyeloidleukemiaattainingsustainedcompletemolecularresponse AT jayjeffrey delayedacutepancreatitisinducedbynilotinibinapatientwithchronicmyeloidleukemiaattainingsustainedcompletemolecularresponse AT charlesmcclainiii delayedacutepancreatitisinducedbynilotinibinapatientwithchronicmyeloidleukemiaattainingsustainedcompletemolecularresponse AT ramandesikan delayedacutepancreatitisinducedbynilotinibinapatientwithchronicmyeloidleukemiaattainingsustainedcompletemolecularresponse |